Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 4/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590742 | 1.00 | JAK3 (0.39) | JAK3JAK2JAK1PTK2ALK | |
| SCHEMBL4589787 | 0.89 | PRKCQ (0.42) | JAK3JAK2JAK1PTK2ALK | |
| SCHEMBL12898542 | 0.89 | PRKCQ (0.42) | JAK3JAK2JAK1PTK2ALK | |
| SCHEMBL1266965 | 0.83 | MAPT (0.39) | PTK2ALKMAPTLMNAPOLB | |
| SCHEMBL12898446 | 0.83 | ALK (0.33) | JAK3JAK2JAK1PTK2ALK | |
| SCHEMBL1266967 | 0.83 | MAPT (0.39) | PTK2ALKMAPTLMNAPOLB | |
| SCHEMBL1266956 | 0.82 | DHFR (0.36) | MAPTLMNASMN1; SMN2ENPP2 | |
| SCHEMBL1264853 | 0.81 | ENPP2 (0.40) | JAK3PTK2ALKMAPTLMNA | |
| SCHEMBL1264852 | 0.81 | ENPP2 (0.40) | JAK3PTK2ALKMAPTLMNA | |
| SCHEMBL12828852 | 0.80 | CYP1A2 (0.38) | JAK3JAK2JAK1PTK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | JAK3 495/4885JAK2 3325/4885JAK1 1500/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | JAK3 1092/4885JAK2 2995/4885JAK1 1243/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | JAK3 1092/4885JAK2 2995/4885JAK1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.